3B Blackbio Dx DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.74×0.74×
1.30×1.36×
54.1%48.4%
0.33×0.28×
1.09×1.10×
18.9%14.9%
19.0%15.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

3BBLACKBIO₹1,359.20

3B Blackbio Dx Limited

· Pharma & Health
₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.74
Interest Burden (Pretax/EBIT) ×1.361.30
EBIT Margin %48.4154.12
Asset Turnover ×0.280.33
Financial Leverage (Assets/Equity) ×1.101.09
ROE (5-step product, year-end total equity) %14.8618.88
ROE (owners' profit / average owners' equity) %15.0219.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.